瑞士诺华的地拉罗司适应症有哪些

It is an iron chelator developed by Novartis and approved for marketing by the FDA in 2005. It is also the first oral iron chelator approved by the FDA for routine use. It is used to treat chronic iron overload caused by blood transfusion in adult and pediatric patients aged 2 years and above and chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome.

In 2012, Deferasirox was approved in the EU for the treatment of patients with chronic iron overload thalassemia aged 6 years and above due to frequent blood transfusions (hematocrit ≥7ml/kg/month). It is also approved for the treatment of chronic iron overload caused by blood transfusions when deferoxamine treatment is contraindicated or insufficient.

In 2010, deferasirox dispersible tablets were approved for marketing in China, bringing new treatment options to Chinese patients. It is also the first-line drug for patients with chronic iron overload caused by blood transfusion. Its use has greatly reduced the mortality of patients and improved their quality of life.

Headquartered in Basel, Switzerland, Novartis is a leading multinational company in the global pharmaceutical and consumer healthcare industries, with operations in more than 140 countries and regions around the world. The recommended starting daily dose of Deferasirox from Novartis Switzerland is 20 mg/kg, and oral administration once a day is simple and convenient, with good patient compliance.

It has been marketed in more than 80 countries. Since the economic and political conditions of each country are different, the prices of deferasirox marketed by Novartis in different countries and regions are not exactly the same. If you need to purchase this drug, you can consult Yiban Travel Overseas Medical Consulting Service Company to learn about the lower-priced version of deferasirox.

Recommended related hot articles: /newsDetail/94056.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.